SCHEMBL2442452

SCHEMBL2442452

Cc1ccc(F)nc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31401280 1.00
SCHEMBL25292508 0.79
SCHEMBL6984571 0.75
SCHEMBL9919116 0.74
SCHEMBL31401060 0.74
SCHEMBL29441266 0.74
SCHEMBL29737998 0.74
SCHEMBL331473 0.74
SCHEMBL9937659 0.74
SCHEMBL6912131 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025092989-A1 SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF 泰州红云制药有限公司 2025-05-08 WO disclosed
US-20250066338-A1 CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2025-02-27 US disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed
WO-2023111144-A1 CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2023-06-22 WO disclosed
WO-2019059161-A1 PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL GERMICIDE HAVING SAME AS ACTIVE INGREDIENT 三井化学アグロ株式会社 2019-03-28 WO disclosed
US-9108937-B2 Positive allosteric modulators of mGluR2 MERCK SHARP & DOHME CORP. (US) 2015-08-18 US disclosed
US-9108937-B2 Positive allosteric modulators of mGluR2 MERCK SHARP & DOHME CORP. (US) 2015-08-18 US disclosed
US-9108937-B2 Positive allosteric modulators of mGluR2 MERCK SHARP & DOHME CORP. (US) 2015-08-18 US disclosed
EP-2542083-B1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME (US) 2015-05-06 EP disclosed
EP-2542083-B1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME (US) 2015-05-06 EP disclosed
US-20130158002-A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME LLC 2013-06-20 US disclosed
US-20130158002-A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME LLC 2013-06-20 US disclosed
US-20130158002-A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME LLC 2013-06-20 US disclosed
EP-2542083-A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 Merck Sharp & Dohme Corp. (US) 2013-01-09 EP disclosed
WO-2011109277-A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed
WO-2011109277-A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed